Communities of practice
New dengue vaccine to launch in 2014
18 May 2011
The French drugmaker Sanofi-Pasteur said on Friday that it hoped to launch a vaccine for dengue fever in 2014 in certain priority countries and could produce some 100 million doses a year.
There is currently no cure or vaccine for dengue fever, but Sanofi’s ChimeriVax, a live attenuated recombinant virus constructed from yellow fever YF 17D in which the envelop protein genes of YF 17D are replaced with the corresponding genes of another flavivirus, is the most clinically advanced candidate. The vaccine entered Phase III clinical testing in Australia in November.
The mosquito-borne disease is a threat to nearly half of the world’s population. Of an estimated 220 million infected each year, two million—mostly children in Latin America and Asia—develop a severe form called dengue hemorrhagic fever.
Sanofi-Pasteur has said in the past that a vaccine against dengue fever could potentially generate sales of more than $1 billion a year.
Is your organisation working against the infectious diseases of poverty?